Last reviewed · How we verify
DEB-TACE plus Sorafenib
DEB-TACE delivers doxorubicin directly to hepatocellular carcinoma via drug-eluting beads, while sorafenib systemically inhibits multiple tyrosine kinases to suppress tumor growth and angiogenesis.
DEB-TACE delivers doxorubicin directly to hepatocellular carcinoma via drug-eluting beads, while sorafenib systemically inhibits multiple tyrosine kinases to suppress tumor growth and angiogenesis. Used for Hepatocellular carcinoma (HCC), intermediate to advanced stage.
At a glance
| Generic name | DEB-TACE plus Sorafenib |
|---|---|
| Sponsor | Guangxi Medical University |
| Drug class | Combination therapy: locoregional chemoembolization + tyrosine kinase inhibitor |
| Target | DEB-TACE: topoisomerase II (doxorubicin); Sorafenib: VEGFR, PDGFR, RAF, FLT3 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
DEB-TACE (drug-eluting bead transarterial chemoembolization) is a locoregional therapy that uses microspheres loaded with doxorubicin to deliver high drug concentrations directly to the tumor vasculature while occluding blood supply. Sorafenib is a multi-kinase inhibitor targeting VEGFR, PDGFR, RAF, and FLT3, which suppresses angiogenesis and tumor cell proliferation systemically. The combination aims to enhance efficacy through complementary mechanisms: local chemotherapy plus vascular disruption combined with systemic tyrosine kinase inhibition.
Approved indications
- Hepatocellular carcinoma (HCC), intermediate to advanced stage
Common side effects
- Hepatotoxicity / elevated liver enzymes
- Hand-foot skin reaction (sorafenib)
- Diarrhea
- Fatigue
- Nausea / vomiting
- Post-embolization syndrome (fever, pain)
Key clinical trials
- Survival Analysis: TACE vs. Combination Therapy in HCC
- TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer (PHASE2, PHASE3)
- Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT (PHASE4)
- A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma (PHASE3)
- DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma (PHASE3)
- Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma (PHASE2)
- Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |